Pakistan’s retail pharma sector surpasses Rs1.049 trillion in salesÂ
Data from IQVIA reveals steep price hikes drive growth as medicine consumption shows minimal increase, raising concerns over affordability
Saudi investors exit Pakistan’s largest pharmacy chain. What happened and why?
From its origins as part of the Servis Group to multiple changes in ownership since its inception in 2005, Servaid has undergone an eventful two decades in existence
Pharmaceuticals: how the locals are beating the multinationals
In a heavily regulated market, the local players have learned to live with the price rules the way they are, while the foreign players still seem to have hope that things will change
Amoxil recall hits GSK Pakistan revenue in otherwise strong year
Deregulated drug pricing allowed the company to improve gross margins, but the recall still caused revenue to decline
Pakistan’s medicinal imports rise by 9.74pc
ISLAMABAD: Pakistan imported medicinal product worth $656.092 million during the first seven months of current fiscal year, showing growth of 9.74 per cent, when...
Afghan trade halt hits Pakistan’s $200 million pharma exports, medicine containers struck at Torkham, Chaman borders
PPMA warns over 50 pharma firms face losses as temperature-sensitive medicines risk expiry; industry urges govt to allow exports on humanitarian grounds
At Searle, revenue growth is now about volumes, not just prices
The company has also managed to secure alternative input suppliers are disruption on trade with India
Pakistan’s pharmaceutical exports hit 34% growth in FY25, marking a two-decade high
Exports of locally produced medicines reach $457 million, with deregulation policy boosting growth
Senate panel alarmed as medicine prices jump 32% after price controls lifted
Health ministry reports some essential drugs have doubled in cost, prompting inquiry into deregulation impact; Pharmaceutical Manufacturers Association disputes the official figures
Pharma sector thrives with 21.79% growth amid economic stagnation
Deregulation policy drives record sales, but patients face rising costs
As Panadol prices stabilise, Haleon’s revenue growth slows
The boost from deregulated drug prices is stalling, causing Haleon to look at new product launches in nutraceuticals and export markets for growth
Searle is lagging the pharmaceutical sector. Its recovery might be just around the corner
The pharmaceutical company has had lackluster numbers in recent times. All that might be about to change
Searle to sell its entire shareholding in Pakistani subsidiary Â
Board approves sale of 90.61% stake to IJARA-led consortium
Searle secures DRAP’s approval for Denosumab biosimilar injections
Company prepares commercial rollout of 60mg and 120mg doses for osteoporosis and oncology care
Where did all the Burnol go?
The household product is missing from pharmacies in Pakistan. But its brand recall still holds
